Q-omics provides the consensus-scored C8orf58 profile across patient tissues and cancer cell-line models. C8orf58 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, C8orf58 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, C8orf58 RNA expression shows 17,412 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, KIRC, and ACC as cancer lineages where C8orf58 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C8orf58 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C8orf58 survival associations across molecular data types. C8orf58 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C8orf58 RNA expression–survival associations across cancer types. High C8orf58 expression shows unfavorable associations in MESO, ACC, KIRP and BLCA, but favorable associations in UVM and ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for C8orf58 RNA expression.
This table summarizes C8orf58 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C8orf58. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C8orf58 shows lower tumor expression in LUAD, KICH and BRCA and higher tumor expression in KIRC, HNSC and LIHC. The KIRC box plot shows higher C8orf58 RNA expression in tumor versus normal tissue (log2 FC = +0.720, t-test p < 0.001).
This table shows molecular features associated with C8orf58 in patient tissues and cancer cell lines. In patient samples, C8orf58 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C8orf58 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
